Antiplatelets in secondary stroke prevention

Frontiers in Neurology

Volumn JUL, Issue , 2011, Pages

  Shulga, Olga ^a   Bornstein, Natan ^b  

^a Volyn Regional Clinical Hospital   (Ukraine)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Antiplatelets; Ischemic stroke; Secondary prevention

Indexed keywords

EID: 84860305547     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2011.00036     Document Type: Article

References (40)

1. Algra,A.,and van Gijn,J. (1999). Cumu-lative meta-analysis of aspirin effi-cacy after cerebral ischaemia of arte-rial origin. J. Neurol. Neurosurg. Psychiatr. 66, 255.
2. Antithrombotic Trialists'Collaboration. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86. doi: 10.1136/bmj.324.7329.71
3. Bhatt, D., Fox, K., Hacke, W., Berger, P., Black, H., Boden, W., Cohen, E., Creager, M., Easton, D., Flather, M., Haffner, S., Hamm, C., Hankey, G., Johnston, C., Mak, K., Mas, J., Montalescot, G., Pearson, T., Steg, G., Steinhubl, S., Weber, M., Brennan, D., Fabry-Ribaudo, L., Booth, J., Topol, E., and CHARISMA Investigators. (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrom-botic events. N.Engl.J.Med.354, 1706-1717.
4. Bhatt, D., Flather, M., Hacke, W., Berger, P., Black, H., Boden, W., Cacoub, P., Cohen, E., Creager, M., Easton, D., Hamm, C., Hankey, G., Johnston, C., Mak, K., Mas, J., Montalescot, G., Pearson, T. P., Steg, P., Steinhubl, S., Weber, M., Fabry-Ribaudo, L., Hu, T., Topol, E., Fox, K., and CHARISMA Investigators. (2007). Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982-1988.
5. Bhatt, D., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F., Furberg, C., Johnson, D., Mahaffey, K., Quigley, E., Harrington, R., Bates, E., Bridges, C., Eisenberg, M., Fer-rari, V., Hlatky, M., Kaul, S., Lind-ner, J., Moliterno, D., Mukherjee, D., Schofield, R., Rosenson, R., Stein, J., Weitz, H., and Wesley, D. J. (2008). ACCF/ACG/AHA 2008 expert con-sensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiol-ogy foundation task force on clini-cal expert. J. Am. Coll. Cardiol. 52, 1502-1517.
6. Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J., Barr, J. D., Bush, R., Cates, C., Crea-ger, M., Fowler, S., Friday, G., Hertzberg, V., McIff, B., Moore, W., Panagos, P., Riles, T., Rosen-wasser, R., and Taylor, A. (2011). ASA/ACCF/AHA/AANN/AANS/AC R/ASNR/CNS/SAIP/SCAI/SIR/SNI S/SVM/SVS guideline on the management of patients with extracranial carotid and verte-bral artery disease. J. Am. Coll. Cardiol. 57, e16-e94. [originally published online Jan 31, 2011; doi:10.1016/j.jacc.2010.11.006].
7. Brunton, L., Lazo, J., and Parker, K. (2005). Goodman and Gilman's The Pharmacological Basis of Therapeu- tics, New York, NY: McGraw-Hill Professional.
8. Campbell, C. L., Smyth, S., Mon-talescot, G., and Steinhubl, S. R. (2007). Aspirin dose for the pre-vention of cardiovascular disease. A systematic review. JAMA 297, 2018-2024.
9. CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopi-dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339.
10. Connolly, S., Pogue, J., Hart, R., Hohn-loser, S., Pfeffer, M., Chrolavi-cius, S., and Yusuf, S. (2009). Effect of clopidogrel added to aspirin in patients with atrial fib-rillation. N.Engl.J.Med.360, 2066-2078.
11. Costa, J., Ferro, J., Matias-Guiu, J., Alvarez-Sabin, J., and Torres, F. (2005). Triflusal for preventing seri-ous vascular events in people at high risk. Cochrane Database Syst. Rev. CD004296.
12. Diener, H., Bogousslavsky, J., Brass, L., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., Rupprecht, H., and MATCH investigators. (2004). Aspirin and clopidogrel compared with clopi-dogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364, 331-337.
13. Diener, H., Cunha, L., Forbes, C., Sive-nius, J., Smets, P., and Lowenthal, A. (1996). European stroke prevention study 2. Dipyridamole and acetyl-salicylic acid in the secondary pre-vention of stroke. J. Neurol. Sci. 143, 1-13.
14. Eikelboom, J., Emery, J., and Hankey, D. (2010). The use of platelet function assays may help to determine appro-priate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. Stroke 41, 2398-2399.
15. Furie, K., Kasner, S., Adams, R., Albers, G., Bush, R., Fagan, S., Halperin, J., Johnston, S., Katzan, I., Kernan, W., Mitchell, P., Ovbi-agele, B., Palesch, Y., Sacco, R., Schwamm, L., Wassertheil-Smoller, S., Turan, T., and Wentworth, D. (2011). Guidelines for the preven-tion of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare profes-sionals from the American Heart Association/American Stroke Asso-ciation. Stroke 42, 227-276.
16. Gorelick, P., Born, G., D'Agostino, R., Hanley, D., Moye, L., and Pepine, C. J. (1999). Therapeutic benefit. Aspirin revisited in light of the intro-duction of clopidogrel. Stroke 30, 1716-1721.
17. Gorelick, P., Richardson, D., Kelly, M., Ruland, S., Hung, E., Har-ris, Y., Kittner, S., Leurgans, S., and African American Antiplatelet Stroke Prevention Study Investi-gators. (2003). Aspirin and ticlo-pidine for prevention of recur-rent stroke in black patients: a randomized trial. JAMA 289, 2947-2957.
18. Gurbel, P., Cummings, C., Bell, C., Alford, A., Meister, A., Serebruany, V., and Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. (2003). Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elec-tive coronary stenting: the plavix reduction of new thrombus occur-rence (PRONTO) trial. Am.HeartJ. 145, 239-247.
19. Halkes, P. H., van Gijn, J., Kappelle, L. J., Koudstaal, P. J., Algra A., and ESPRIT Study Group. (2006). Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): ran-domized controlled trial. Lancet 367, 1665-1673.
20. Halkes, P. H. A., van Gijn, J., Kap-pelle, L. J., Koudstaal, P. J., Algra, A., and ESPRIT study group. (2009). Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. J. Neurol. Neurosurg. Psychiatry 80, 437-439.
21. Hankey, G. J., Spiesser, J., Hakimi, Z., Bego, G., Carita, P., and Gabriel, S. (2007). Rate, degree, and predictors of recovery from disability follow-ing ischemic stroke. Neurology 68, 1583-1587.
22. Hankey, J., Hacke, W., Easton, D., John-ston, C., Mas. L., Brennan, D., Bhatt, D., Fox, K., and Topol, E. (2010). Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a pre-specified substudy of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (CHARISMA) trial. Stroke 41, 1679-1683.
23. Holmes, D., Dehmer, G., Kaul, S., Leifer, D., O'Gara, P., and Stein, M. (2010). ACFF/AHA clopidogrel clinical alert: approach to the FDA "boxed warning." Circulation 122, 537-557.
24. Kennedy, J., Hill, M. D., Ryckborst, K. J., Eliasziw, M., Demchuk, A. M., and Buchan, A. M. (2007). Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 6, 961-969.
25. Lanas, A., Garcia-Rodriguez, L., Arroyo, M., Gomollón, F., Feu, F., González-Pérez, A., Zapata, E., Bástida, G., Rodrigo, L., Santolaria, S., Güell, M., de Argila, C., Quintero, E., Borda, F., and Piqué, J. (2006). Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55, 1731-1738.
26. McQuaid, K. R., and Laine, L. (2006). Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized con-trolled trials. Am.J.Med.119, 624-638.
27. Mega, J., Close, S., Wiviott, S., Shen, L., Hockett, R., Brandt, J., Walker, J., Antman, E., Macias, W., Braun-wald, E., and Sabatine, M. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362.
28. Ohira, T., Shahar, E., Chambless, L., Rosamond, W., Mosley, J., and Fol-som, A. (2006). Risk factors for ischemic stroke subtypes: the ather-osclerosis risk in communities study. Stroke 37, 2493-2498.
29. Qureshi, A., Luft, A., Sharma, M., Guterman, L., and Hopkins, L. (2000). Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures, part I: pathophysiological and pharmaco-logical features. Neurosurgery 46, 1344-1359.
30. Ringleb, P., Bousser, M., Ford, G., Bath, P., Brainin, M., Caso, V., Cervera, A., Chamorro, A., Cordonnier, C., Csiba, L., Davalos, A., Diener, H., Ferro, J., Hacke, W., Hennerici, M., Kaste, M., Langhorne, P., Lees, K., Leys, D., Lodder, J., Hugh, S., Markus, H., Mas, J., Mattle, H., Muir, K., Norrving, B., Obach,V., Paolucci, S., Ringelstein, E., Schellinger, P., Sivenius, J., Skvortsova, V., Sunnerhagen, K., Thomassen, L., Toni, D., von Kummer, R., Wahlgren, N., Walker, M., and Wardlaw, J. (2008) ESO - Guidelines for management of ischaemic stroke. Cerebrovasc. Dis. 25, 457-507.
31. Roth, G. J., and Calverley, D. C. (1994). Aspirin, platelets, and thrombo-sis: theory and practice. Blood 83, 885-898.
32. Sacco, R., Diener, H., Yusuf, S., Cotton, D., Ounpuu, S., Lawton, W., Palesch, Y., Martin, R., Albers, G., Bath, P., Bornstein, N., Chan, B., Chen, S., Cunha, L., Dahlöf, B., De Keyser, J., Donnan, G., Estol, C., Gorelick, P., Gu, V., Hermansson, K., Hilbrich, L., Kaste, M., Lu, C., Machnig, T., Pais, P., Roberts, R., Skvortsova, V., Teal, P., Toni, D., VanderMaelen, C., Voigt, T., Weber, M., Yoon, B., and PRoFESS Study Group. (2008). Aspirin and extended-release dipyri-damole versus clopidogrel for recur-rent stroke. N.Engl.J.Med.359, 1238-1251.
33. Schuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R., Damcott, C., Pakyz, R., Tantry, U., Gibson, Q., Pollin, T., Post, W., Parsa, A., Mitchell, B., Faraday, N., Herzog, W., and Gurbel, P. (2009). Asso-ciation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-858.
34. Selim, M., and Molina, C. (2010). Platelet function assays in stroke management: more study is needed. Stroke. 41, 2396-2397.
35. Shin, D., Lee, P., and Bang, O. (2005). Mechanisms of recurrence in sub-types of ischemic stroke: a hospital-based follow-up study. Arch. Neurol. 62, 1232-1237.
36. Siller-Matula, J., Spiel, A., Lang, I., Kreiner, G., Christ, G., and Jilma, B. (2009). Effects of pantopra-zole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1-148.e5.
37. Steg, P. G., Bhatt, D. L., Wilson, P. W., D'Agostino, Sr. R., Ohman, E. M., Rother, J., Liau, C., Hirsch, A., Mas, J., Ikeda, Y., Pencina, M., Goto, S., and REACH Registry Inves-tigators. (2007). One-year cardio-vascular event rates in outpatients with atherothrombosis. JAMA 297, 1197-1206.
38. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. (2001). Effects of clopidogrel in addition aspirin in patients with acute coronary syn-dromes without ST-segment ele-vation. N.Engl.J.Med.345, 494-502.
39. The Dutch TIA Trial Study Group. (1991). A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl.J.Med.325, 1261-1266.
40. The ESPS-2 Group. (1997). European Stroke Prevention Study: 2. Effi-cacy and safety data. Secondary end-points. J. Neurol. Sci. 151(Suppl.), S27-S37.